Try our mobile app

Switch to company model in classical logic    *

General information

Country: CHINA

Sector: Biotechnology

Categories: @china   

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
Website: beigene.com



Growth: Good revenue growth rate 40.9%, there is slowdown compared to average historical growth rates 60.2%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is negative, -7.7%. On average the margin is improving steadily. Gross margin is high, +86.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 8.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 42.6% higher than minimum and 32.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.8x by EV / Sales multiple , the company can be 51.3% undervalued

Key Financials (Download financials)

Ticker: BGNE
Share price, USD:  (0.0%)184.71
year average price 184.70  


year start price 181.89 2024-12-29

min close price 181.89 2024-12-29

max close price 184.71 2024-12-31

current price 184.71 2025-12-28
Common stocks: 82 691 313

Dividend Yield:  0.0%
EV / Sales: 2.5x
Margin (EBITDA LTM / Revenue): -7.7%
Fundamental value created in LTM:
Market Cap ($m): 15 274
Net Debt ($m): -3 017
EV (Enterprise Value): 12 257
Price to Book: 3.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-13businesswire.com

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

2025-04-29businesswire.com

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

2025-04-17businesswire.com

BeiGene to Announce First Quarter 2025 Financial Results on May 7

2025-04-03businesswire.com

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

2025-02-21zacks.com

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

2025-02-13businesswire.com

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

2024-12-27businesswire.com

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

2024-12-12businesswire.com

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

2024-12-09businesswire.com

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

2024-12-02businesswire.com

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-09-30 2024-08-07 2024-05-08 2024-02-26 2023-11-09 2023-08-02 2023-05-04 2023-02-27 2022-11-09
acceptedDate 2025-11-06 06:07:16 2025-08-06 06:05:46 2024-09-30 00:00:00 2024-08-07 06:07:59 2024-05-08 06:09:45 2024-02-26 06:16:27 2023-11-09 16:14:07 2023-08-02 06:23:42 2023-05-04 07:17:19 2023-02-27 07:35:59 2022-11-09 07:12:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 412M 1 315M 1 002M 929M 752M 634M 781M 595M 448M 380M 388M
costOfRevenue 197M 165M 170M 138M 125M 129M 96M 519M 82M 520M 503M
grossProfit 1 216M 1 151M 831M 791M 627M 506M 685M 77M 366M -139M -115M
grossProfitRatio 0.861 0.875 0.83 0.851 0.834 0.797 0.877 0.129 0.817 -0.367 -0.297
researchAndDevelopmentExpenses 524M 525M 496M 454M 461M 473M 453M 423M 409M 1 262M 426M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 529M 538M 455M 444M 427M 417M 364M 395M 328M 329M 323M
otherExpenses 0 0 0 0 2M 17M 337M -64M -408M -1 262M -426M
operatingExpenses 1 053M 1 063M 951M 898M 888M 890M 818M 395M 329M 329M 323M
costAndExpenses 1 249M 1 227M 1 122M 1 036M 1 013M 1 018M 914M 914M 737M 849M 826M
interestIncome 0 0 11M 13M 16M 21M 27M 15M 16M 0 0
interestExpense 0 0 0 0 0 9M 18M 5M -34M 18M 13M
depreciationAndAmortization 37M 0 71M 25M 25M 24M 22M 22M 20M 188 000 16M
ebitda 184M 88M -49M -82M -261M -360M -134M -296M -371M -468M -422M
ebitdaratio 0.131 0.067 -0.049 -0.088 -0.348 -0.567 -0.171 -0.498 -0.829 -1.232 -1.089
operatingIncome 163M 88M -120M -107M -261M -384M -134M -319M -371M -469M -438M
operatingIncomeRatio 0.115 0.067 -0.12 -0.115 -0.348 -0.605 -0.171 -0.535 -0.829 -1.233 -1.131
totalOtherIncomeExpensesNet -16M 12M 22M 1M 18M 33M 363M -64M 34M 38M -113M
incomeBeforeTax 147M 100M -98M -106M -243M -351M 229M -367M -337M -431M -551M
incomeBeforeTaxRatio 0.104 0.076 -0.098 -0.114 -0.324 -0.553 0.294 -0.617 -0.752 -1.134 -1.422
incomeTaxExpense 22M 5M 23M 14M 8M 17M 14M 14M 11M 14M 6M
netIncome 125M 94M -121M -120M -251M -368M 215M -381M -348M -445M -558M
netIncomeRatio 0.088 0.072 -0.121 -0.13 -0.334 -0.579 0.276 -0.64 -0.778 -1.172 -1.438
eps 14.69 11.31 -1.15 -1.15 -1.85 -3.53 2.06 -3.64 -3.34 -4.29 -5.39
epsdiluted 14.17 10.92 -1.15 -1.15 -1.85 -3.53 2.01 -3.64 -3.34 -4.29 -5.39
weightedAverageShsOut 110M 108M 106M 105M 136M 104M 105M 105M 104M 104M 103M
weightedAverageShsOutDil 115M 113M 106M 105M 136M 104M 107M 105M 104M 104M 103M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-09-30 2024-08-07 2024-05-08 2024-02-26 2023-11-09 2023-08-02 2023-05-04 2023-02-27 2022-11-09
acceptedDate 2025-11-06 06:07:16 2025-08-06 06:05:46 2024-09-30 00:00:00 2024-08-07 06:07:59 2024-05-08 06:09:45 2024-02-26 06:16:27 2023-11-09 16:14:07 2023-08-02 06:23:42 2023-05-04 07:17:19 2023-02-27 07:35:59 2022-11-09 07:12:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 4 037M 2 756M 2 702M 2 593M 2 762M 3 183M 3 067M 3 410M 3 539M 3 870M 4 197M
shortTermInvestments 0 0 0 0 43M 3M 107M 106M 294M 665M 872M
cashAndShortTermInvestments 4 037M 2 756M 2 702M 2 593M 2 805M 3 186M 3 174M 3 516M 3 833M 4 540M 5 069M
netReceivables 863M 771M 603M 588M 467M 396M 355M 338M 332M 173M 203M
inventory 532M 503M 432M 443M 447M 416M 317M 321M 297M 282M 291M
otherCurrentAssets 233M 281M 175M 215M 188M 206M 24M 41M 42M 191M 186M
totalCurrentAssets 5 664M 4 310M 3 912M 3 839M 3 908M 4 203M 4 054M 4 401M 4 704M 4 713M 5 749M
propertyPlantEquipmentNet 1 768M 1 762M 1 713M 1 620M 1 506M 1 419M 1 289M 1 145M 1 054M 846M 830M
goodwill 0 0 0 0 0 0 0 109 000 109 000 109 000 109 000
intangibleAssets 64M 65M 54M 54M 55M 109M 54M 47M 40M 95M 41M
goodwillAndIntangibleAssets 64M 65M 54M 54M 55M 109M 54M 47M 40M 95M 41M
longTermInvestments 0 0 138M 140M 146M 92M 89M 96M 98M 92M 96M
taxAssets 0 0 0 0 -1 -52M 30M 39M 0 0 0
otherNonCurrentAssets 136M 162M 14M 60M 53M 33M 9M 2M 61M -186M 10M
totalNonCurrentAssets 1 968M 1 988M 1 919M 1 873M 1 760M 1 602M 1 471M 1 327M 1 252M 846M 977M
otherAssets 0 0 0 0 1 2 0 0 0 820M 0
totalAssets 7 633M 6 298M 5 831M 5 712M 5 668M 5 805M 5 525M 5 729M 5 957M 6 379M 6 726M
accountPayables 384M 361M 308M 333M 357M 315M 342M 267M 241M 295M 252M
shortTermDebt 829M 826M 882M 887M 846M 710M 352M 445M 306M 353M 466M
taxPayables 11M 6M 49M 5M 27M 23M 43M 56M 62M 44M 49M
deferredRevenue 0 0 0 0 27M 23M 300 000 159M 185M 256M 145M
otherCurrentLiabilities 1 145M 1 018M 787M 713M 651M 762M 589M 535M 521M 114M 549M
totalCurrentLiabilities 2 368M 2 210M 2 025M 1 939M 1 882M 1 810M 1 283M 1 405M 1 255M 1 018M 1 411M
longTermDebt 191M 200M 220M 221M 199M 198M 228M 233M 239M 538M 245M
deferredRevenueNonCurrent 0 0 32M 0 33M 300 000 34M 59M 75M 80M 188M
deferredTaxLiabilitiesNonCurrent 47M 44M 16M 16M 16M 16M 16M 16M 16M 16M 15M
otherNonCurrentLiabilities 897M 74M 101M 171M 144M 209M 200M 217M 215M 344M -203M
totalNonCurrentLiabilities 1 135M 318M 369M 407M 393M 424M 478M 525M 545M 978M 660M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 0 0 50M 53M 18M 22M 49M 49M 57M 59M 61M
totalLiabilities 3 503M 2 528M 2 395M 2 346M 2 274M 2 234M 1 762M 1 930M 1 799M 1 996M 2 071M
preferredStock 0 0 0 0 0 0 0 145M 0 0 0
commonStock 144 000 143 000 138 000 137 000 136 000 135 000 135 000 137 000 136 000 135 000 135 000
retainedEarnings -8 386M -8 511M -8 455M -8 334M -8 213M -7 962M -7 594M -7 810M -7 429M -7 080M -6 635M
accumulatedOtherComprehensiveIncomeLoss -101M -114M -84M -140M -132M -99M -145M -144M -59M -77M -162M
othertotalStockholdersEquity 12 617M 12 395M 11 974M 11 840M 11 705M 11 599M 11 503M 11 607M 11 645M 11 541M 11 452M
totalStockholdersEquity 4 129M 3 770M 3 436M 3 366M 3 360M 3 537M 3 763M 3 799M 4 157M 4 383M 4 655M
totalEquity 4 129M 3 770M 3 436M 3 366M 3 360M 3 537M 3 763M 3 799M 4 157M 4 383M 4 655M
totalLiabilitiesAndStockholdersEquity 7 633M 6 298M 5 831M 5 712M 5 668M 5 805M 5 525M 5 729M 5 957M 6 379M 6 726M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 633M 6 298M 5 831M 5 712M 5 668M 5 805M 5 525M 5 729M 5 957M 6 379M 6 726M
totalInvestments 0 0 138M 140M 189M 95M 107M 106M 294M 757M 968M
totalDebt 1 020M 1 026M 1 101M 1 090M 1 063M 930M 580M 678M 545M 891M 711M
netDebt -3 017M -1 730M -1 600M -1 503M -1 699M -2 253M -2 488M -2 733M -2 993M -2 978M -3 487M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-09-30 2024-08-07 2024-05-08 2024-02-26 2023-11-09 2023-08-02 2023-05-04 2023-02-27 2022-11-09
acceptedDate 2025-11-06 06:07:16 2025-08-06 06:05:46 2024-09-30 00:00:00 2024-08-07 06:07:59 2024-05-08 06:09:45 2024-02-26 06:16:27 2023-11-09 16:14:07 2023-08-02 06:23:42 2023-05-04 07:17:19 2023-02-27 07:35:59 2022-11-09 07:12:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 125M 94M -121M -120M -251M -368M 215M -381M -348M -445M -553M
depreciationAndAmortization 37M 36M 71M 25M 25M 24M 22M 22M 20M 18M 16M
deferredIncomeTax 0 0 0 0 0 -46 000 750 000 -51 000 36 000 2M -7M
stockBasedCompensation 141M 151M 115M 131M 89M 93M 96M 103M 75M 78M 78M
changeInWorkingCapital 0 0 130M -113M -155M 17M -58M -35M -294M -197 000 -86M
accountsReceivables -94M -42M -30M -94M -80M -45M -12M 5M -136M 19M -23M
inventory -29M 2M 24M 1M -37M -89M 1M -41M -13M 19M -44M
accountsPayables 28M -4M 11M -44M 46M -10M 64M -10M -23M -9M 35M
otherWorkingCapital 0 0 125M 23M -84M 160M -112M 11M -122M -30M -54M
otherNonCashItems 100M -17M -7M -17M 194M 12M -354M -3M -17M 30M -11M
netCashProvidedByOperatingActivities 403M 264M 188M -96M -309M -222M -78M -294M -564M -318M -562M
investmentsInPropertyPlantAndEquipment -48M -44M -134M -110M -161M -167M -182M -121M -126M -170M -129M
acquisitionsNet 0 0 0 0 0 -94M 24M 0 0 144M 0
purchasesOfInvestments 0 0 0 0 0 -1M -4M -11M -1M -3M -3M
salesMaturitiesOfInvestments 0 0 0 0 3M 106M 19 000 191M 377M 211M 301M
otherInvestingActivites -1M -23M -227 000 -1M -51M 94M -24M 9M -9M -144M -20M
netCashUsedForInvestingActivites -49M -67M -134M -111M -210M -63M -186M 68M 241M 39M 169M
debtRepayment 0 0 -4M 14M -148M -344M -101M -15M -51M -272M -30M
commonStockIssued 0 0 0 6M 15M 3M 17M 4M 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 961M 35M 16M 9M 162M 687M 7M 178M 32M 161M 150M
netCashUsedProvidedByFinancingActivities 961M 35M 13M 23M 162M 347M -77M 166M -20M -110M 120M
effectOfForexChangesOnCash 0 0 28M -6M -22M 42M 525 000 -62M 11M 65M -63M
netChangeInCash 1 324M 255M 95M -190M -421M 104M -341M -122M -331M -325M -335M
cashAtEndOfPeriod 4 111M 2 786M 2 713M 2 618M 2 762M 3 183M 3 081M 3 422M 3 544M 3 875M 4 201M
cashAtBeginningOfPeriod 2 786M 2 531M 2 618M 2 807M 3 183M 3 079M 3 422M 3 544M 3 875M 4 201M 4 535M
operatingCashFlow 403M 264M 188M -96M -309M -222M -78M -294M -564M -318M -562M
capitalExpenditure -48M -44M -134M -110M -161M -167M -182M -121M -126M -170M -129M
freeCashFlow 354M 220M 55M -206M -470M -389M -260M -415M -689M -488M -691M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)

SEC forms

Show financial reports only

SEC form 10
2025-11-06 06:07 ET
BeiGene reported for 2025 q3
SEC form 8
2025-11-06 06:03 ET
BeiGene published news for 2025 q3
SEC form 8
2025-11-06 06:03 ET
BeiGene reported for 2025 q3
SEC form 8
2025-08-29 06:52 ET
BeiGene published news for 2025 q2
SEC form 8
2025-08-29 06:52 ET
BeiGene published news for 2025 q2
SEC form 10
2025-08-06 10:05 ET
BeiGene reported for 2025 q2
SEC form 8
2025-08-06 10:02 ET
BeiGene published news for 2025 q2
SEC form 8
2025-08-06 10:02 ET
BeiGene reported for 2025 q2
SEC form 10
2025-05-07 10:09 ET
BeiGene published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
BeiGene reported for 2025 q1
SEC form 8
2025-05-07 00:00 ET
BeiGene published news for 2025 q1
SEC form 8
2025-05-07 00:00 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-29 21:03 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-28 20:09 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-28 00:00 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-28 00:00 ET
BeiGene published news for 2025 q1
SEC form 10
2025-02-27 11:12 ET
BeiGene published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
BeiGene reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
BeiGene published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
BeiGene published news for 2024 q4
SEC form 10
2024-11-12 06:06 ET
BeiGene reported for 2024 q3
SEC form 8
2024-11-12 06:03 ET
BeiGene published news for 2024 q3
SEC form 8
2024-11-12 06:03 ET
BeiGene published news for 2024 q3
SEC form 10
2024-11-12 00:00 ET
BeiGene published news for 2024 q3
SEC form 8
2024-08-29 00:00 ET
BeiGene published news for 2024 q2
SEC form 8
2024-08-29 00:00 ET
BeiGene published news for 2024 q2
SEC form 10
2024-08-07 06:07 ET
BeiGene published news for 2024 q2
SEC form 8
2024-08-07 00:00 ET
BeiGene published news for 2024 q2
SEC form 8
2024-08-07 00:00 ET
BeiGene published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
BeiGene reported for 2024 q2
SEC form 10
2024-05-08 06:09 ET
BeiGene reported for 2024 q1
SEC form 8
2024-05-08 06:06 ET
BeiGene published news for 2024 q1
SEC form 8
2024-05-08 06:06 ET
BeiGene published news for 2024 q1
SEC form 10
2024-05-08 00:00 ET
BeiGene published news for 2024 q1
SEC form 8
2024-04-26 00:00 ET
BeiGene published news for 2024 q1
SEC form 8
2024-04-26 00:00 ET
BeiGene published news for 2024 q1
SEC form 10
2024-02-26 06:16 ET
BeiGene published news for 2023 q4
SEC form 8
2024-02-26 06:02 ET
BeiGene reported for 2023 q4
SEC form 8
2024-02-26 06:02 ET
BeiGene published news for 2023 q4
SEC form 10
2024-02-26 00:00 ET
BeiGene published news for 2023 q4
SEC form 10
2023-11-09 16:14 ET
BeiGene reported for 2023 q3
SEC form 8
2023-11-09 16:08 ET
BeiGene published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
BeiGene published news for 2023 q3
SEC form 8
2023-08-29 00:00 ET
BeiGene published news for 2023 q2
SEC form 10
2023-08-02 06:23 ET
BeiGene reported for 2023 q2
SEC form 6
2023-08-02 06:13 ET
BeiGene published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
BeiGene published news for 2023 q2
SEC form 6
2023-07-24 16:13 ET
BeiGene published news for 2023 q2
SEC form 6
2023-07-11 06:01 ET
BeiGene published news for 2023 q2
SEC form 6
2023-06-20 18:59 ET
BeiGene published news for 2023 q1
SEC form 6
2023-06-20 18:37 ET
BeiGene published news for 2023 q1
SEC form 6
2023-06-15 16:43 ET
BeiGene published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
BeiGene published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
BeiGene published news for 2023 q1
SEC form 8
2023-04-25 00:00 ET
BeiGene published news for 2023 q1
SEC form 10
2023-02-27 00:00 ET
BeiGene reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
BeiGene reported for 2022 q4
SEC form 10
2022-11-09 00:00 ET
BeiGene reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
BeiGene reported for 2022 q3
SEC form 8
2022-08-30 00:00 ET
BeiGene published news for 2022 q2
SEC form 10
2022-08-08 00:00 ET
BeiGene reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
BeiGene reported for 2022 q2
SEC form 10
2022-05-09 00:00 ET
BeiGene reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
BeiGene reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
BeiGene published news for 2022 q1
SEC form 10
2022-02-28 00:00 ET
BeiGene published news for 2021 q4
SEC form 8
2022-02-25 00:00 ET
BeiGene published news for 2021 q4
SEC form 8
2021-11-16 00:00 ET
BeiGene published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
BeiGene published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
BeiGene published news for 2021 q3
SEC form 8
2021-08-05 00:00 ET
BeiGene published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
BeiGene published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
BeiGene published news for 2021 q2
SEC form 8
2021-06-30 00:00 ET
BeiGene published news for 2021 q1
SEC form 8
2021-05-14 00:00 ET
BeiGene published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
BeiGene published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
BeiGene published news for 2021 q1